

# Andreas D Hartkopf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7768311/publications.pdf>

Version: 2024-02-01

92  
papers

1,977  
citations

331670

21  
h-index

289244

40  
g-index

124  
all docs

124  
docs citations

124  
times ranked

2721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 719-726.	2.5	6
2	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e16128.	4.3	6
3	Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. <i>Cancers</i> , 2022, 14, 635.	3.7	6
4	A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 826302.	3.5	10
5	Update Breast Cancer 2021 Part 4 "Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 206-214.	1.8	4
6	Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 875-885.	1.7	9
7	How previous treatment changes the metabolomic profile in patients with metastatic breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2115-2122.	1.7	4
8	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
9	Abstract PS17-42: A fast and effective 3D preclinical assay system comprised of patient derived breast cancer microtumors combined with DigiWest protein signaling pathway analyses for therapeutic response prediction (Project PRIMO). , 2021, , .		0
10	Update Breast Cancer 2020 Part 5 "Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	1.8	6
11	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer "Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
12	Update Breast Cancer 2021 Part 2 "Advanced Stages, Long-Term Consequences and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 539-548.	1.8	6
13	Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1040-1040.	1.6	10
14	Update Breast Cancer 2021 Part 1 "Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	1.8	10
15	The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Anticancer Research</i> , 2021, 41, 2849-2858.	1.1	1
16	Update Breast Cancer 2021 Part 3 "Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 654-665.	1.8	4
17	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
18	An Activity Tracker"Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). <i>JMIR Research Protocols</i> , 2021, 10, e28524.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	2.8	24
20	Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study. <i>JMIR Cancer</i> , 2021, 7, e25776.	2.4	6
21	Clinical Trials of Oncolytic Viruses in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 803050.	2.8	13
22	Update Mammakarzinom 2021 Teil 1 â€“ PrÃvention und frÃ¼he Krankheitsstadien. <i>Senologie - Zeitschrift fÃ¼r Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390.	0.0	0
23	Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 111-121.	2.8	22
24	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	3.7	6
25	Update Breast Cancer 2020 Part 3 â€“ Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114.	1.8	12
26	Update Breast Cancer 2020 Part 4 â€“ Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	1.8	11
27	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	1.8	4
28	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	2.6	1
29	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€” Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	2.2	34
30	Update Breast Cancer 2020 Part 1 â€“ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 277-287.	1.8	16
31	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	3.4	12
32	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1055.	3.7	19
33	Update Breast Cancer 2020 Part 2 â€“ Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398.	1.8	12
34	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. <i>BMC Cancer</i> , 2019, 19, 787.	2.6	10
35	Update Breast Cancer 2019 Part 4 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	1.8	18
36	Update Breast Cancer 2019 Part 5 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	1.8	16

#	ARTICLE	IF	CITATIONS
37	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019, 19, 611.	2.6	5
38	Update Breast Cancer 2019 Part 1 â€“ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	1.8	17
39	Update Breast Cancer 2019 Part 3 â€“ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	1.8	26
40	Update Breast Cancer 2019 Part 2 â€“ Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	1.8	21
41	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2114-2121.	5.1	6
42	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27
43	Translational Highlights in Breast and Ovarian Cancer 2019 â€“ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	1.8	11
44	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
45	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
46	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
47	Germline BRCA1 and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry. <i>Journal of Clinical Oncology</i> , 2019, 37, 1048-1048.	1.6	3
48	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tumor Symptom Burden (FACT-B-TS) in Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10004.	4.3	29
49	RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozoleâ€”Results of the second interim analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 1061-1061.	1.6	0
50	Update Breast Cancer 2018 (Part 1) â€“ Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
51	A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 305-309.	2.5	2
52	Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 785-790.	1.7	6
53	Update Breast Cancer 2018 (Part 2) â€“ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
54	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€“ Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54

#	ARTICLE	IF	CITATIONS
55	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
56	C05â€¦BRCA mutations are associated with higher CAG numbers found in various polyglutamine disorders. , 2018, , .		0
57	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	1.8	3
58	Update Breast Cancer 2018 (Part 3) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	1.8	8
59	Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms. <i>Anticancer Research</i> , 2018, 38, 4047-4056.	1.1	5
60	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	2.5	28
61	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. <i>Journal of Clinical Oncology</i> , 2018, 36, 522-522.	1.6	17
62	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245.	1.7	42
63	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
64	Update Breast Cancer 2017 â€œ Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19
65	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. <i>JMIR Cancer</i> , 2017, 3, e11.	2.4	38
66	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322.	4.3	48
67	Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 115-124.	3.0	20
68	Early dissemination seeds metastasis in breast cancer. <i>Nature</i> , 2016, 540, 552-558.	27.8	550
69	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 277-290.	2.5	23
70	Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 91-95.	2.5	9
71	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
72	The DETECT study concept: Individualized therapy of metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS634-TPS634.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients. <i>Anticancer Research</i> , 2016, 36, 2345-51.	1.1	16
74	Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 51-55.	2.5	1
75	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS11109-TPS11109.	1.6	0
76	Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11003-11003.	1.6	0
77	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	2.5	45
78	Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 345-351.	2.5	16
79	Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients – Results from a large single-centre analysis. <i>European Journal of Cancer</i> , 2014, 50, 2550-2559.	2.8	60
80	Bisphosphonate treatment of primary breast cancer patients with disseminated tumor cells in the bone marrow.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11044-11044.	1.6	0
81	Disseminated tumor cells in bone marrow of patients with endometrial and cervical cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5598-5598.	1.6	0
82	The persistence of disseminated tumor cells after systemic therapy and their influence on prognosis in early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1030-1030.	1.6	0
83	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11012-11012.	1.6	0
84	Dormancy in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 183.	1.8	25
85	Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 501-508.	2.5	15
86	HER2-Positive DTCs/CTCs in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2012, 195, 203-215.	1.8	19
87	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1090-1090.	1.6	0
88	Accuracy of MRI, mammography (MG), and 2D and 3D ultrasound (2DUS/3DUS) in determining the pathologic tumor response after neoadjuvant chemotherapy (NACT) in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1067-1067.	1.6	0
89	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5042-5042.	1.6	2
90	Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21003-e21003.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Oncolytic virotherapy of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2011, 120, 302-310.	1.4	26
92	Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Anticancer Research</i> , 2011, 31, 979-84.	1.1	59